### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### **SCHEDULE 13G/A**

Under the Securities Exchange Act of 1934 (Amendment No. 2)\*

# Amicus Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share (Title of Class of Securities)

> 03152W 10 9 (CUSIP Number)

December 31, 2023 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 $\Box$  Rule 13d-1(b)

 $\boxtimes$  Rule 13d-1(c)

 $\Box$  Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

#### CUSIP No. 03152W 10 9

1	1 NAMES OF REPORTING PERSONS							
	р ( <sup>:</sup>	. 1						
2	Perceptive		ISOTS LLC APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
2		пе <i>F</i> (b)						
	(u) 🗆	(0)						
3	SEC USE ONLY							
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION							
	Delaware	-						
		5	SOLE VOTING POWER					
Л			0					
	JMBER OF SHARES	6	SHARED VOTING POWER					
	VEFICIALLY							
0	WNED BY		28,057,456					
DI	EACH	7	SOLE DISPOSITIVE POWER					
	EPORTING PERSON		0					
1	WITH:	8	0 SHARED DISPOSITIVE POWER					
		0	SHARED DISPOSITIVE FOWER					
			28,057,456					
9	AGGREGA	TE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	28,057,456							
10	CHECK BO	JX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11		OF	CLASS REPRESENTED BY AMOUNT IN ROW 9					
	9.6%							
12	12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)							
	<b>T</b> 4							
	IA							

#### CUSIP No. 03152W 10 9

1	NAMES O	JAMES OF REPORTING PERSONS						
	Joseph Ede							
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □							
	(a) 🗆	(D)						
3	SEC USE ONLY							
5								
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION							
	United States of America							
		5	SOLE VOTING POWER					
	MBER OF							
	SHARES	6	SHARED VOTING POWER					
	IEFICIALLY WNED BY		28,057,456					
0	EACH	7	SOLE DISPOSITIVE POWER					
RE	PORTING	-						
	PERSON		0					
	WITH:	8	SHARED DISPOSITIVE POWER					
	L G G D D G L		28,057,456					
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	28,057,456							
10			F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9					
	9.6%							
12	TYPE OF I	(EP	ORTING PERSON (SEE INSTRUCTIONS)					
	IN							
	11.1							

#### CUSIP No. 03152W 10 9

1	1 NAMES OF REPORTING PERSONS						
	Perceptive	Life	Sciences Master Fund, Ltd.				
2							
	(a) 🗆	(b)					
3	SEC USE ONLY						
-							
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION						
	CITIZEIUS						
	Cayman Isl	ando					
	Cayman Isi	5	SOLE VOTING POWER				
		5	SOLE VOTING TOWER				
			0				
	JMBER OF	6	SHARED VOTING POWER				
	SHARES		SHAKED VOTING POWER				
	IEFICIALLY						
0	WNED BY	_	28,057,456				
рг	EACH	7	SOLE DISPOSITIVE POWER				
	EPORTING PERSON						
1	WITH:		0				
	WIII.	8	SHARED DISPOSITIVE POWER				
			28,057,456				
9	AGGREGA	ΛTE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	28,057,456						
10	CHECK BO	DX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9				
	9.6%						
12							
	СО						

#### Item 1(a). <u>Name of Issuer</u>:

Amicus Therapeutics, Inc. (the "Issuer")

#### Item 1(b). Address of Issuer's Principal Executive Offices:

47 Hulfish Street, Princeton, New Jersey 08542

#### Item 2(a). <u>Names of Persons Filing</u>:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

#### Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation

#### Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, par value \$0.01 per share ("Common Stock")

#### Item 2(e). <u>CUSIP Number</u>:

03152W 10 9

### Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

#### Item 4. <u>Ownership</u>.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 293,257,438 outstanding shares of Common Stock, as reported in the Issuer's Form S-3 filed on November 8, 2023.

The Master Fund directly holds 28,057,456 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

#### Item 5. <u>Ownership of Five Percent or Less of a Class</u>.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\Box$ .

#### Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>.

Not applicable.

## Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

- Item 8.
   Identification and Classification of Members of the Group.

   Not applicable.
   Not applicable.
- Item 9. Notice of Dissolution of Group.

Not applicable.

#### Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

#### **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

PERCEPTIVE ADVISORS LLC

By: <u>/s/ Joseph Edelman</u> Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

#### AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member